Form 4: Labcorp Officer's Stock Transactions Post RSU Vesting

Labcorp's SVP and Chief Accounting Officer, Peter J. Wilkinson, reported common stock acquisitions and tax-related dispositions following the vesting of Restricted Stock Units.

Summary

• Peter J. Wilkinson, SVP, Chief Accounting Officer of Labcorp Holdings Inc., reported transactions on February 11, 2026.
• Acquired 536 shares of Common Stock upon the vesting of Restricted Stock Units (RSUs).
• Disposed of 160 shares of Common Stock at a price of $289.89 per share to satisfy tax withholding obligations.
• Acquired an additional 160 shares of Common Stock from another RSU vesting event.
• Disposed of 46 shares of Common Stock at a price of $289.89 per share for further tax withholding.
• Following these transactions, Wilkinson beneficially owns 2,518.2194 shares of Common Stock directly.
• The Restricted Stock Units that vested were part of a grant that vests in three equal annual installments beginning on February 11, 2026.
• The aggregate number of Restricted Stock Units beneficially owned by the reporting person after these transactions is 1,968.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine insider transaction related to executive compensation, reflecting the vesting of previously granted equity awards and standard tax withholding, which is generally neutral but indicates ongoing executive alignment.

Positives

• The vesting of Restricted Stock Units indicates continued long-term incentive alignment between management and shareholders.
• The acquisition of common stock through RSU vesting increases the officer's direct ownership in the company, reinforcing commitment.

Negatives

• Disposition of shares for tax withholding reduces the officer's direct beneficial ownership, though this is a standard and expected practice.

Future Outlook

The filing indicates future vesting events for Restricted Stock Units, as the grant vests in three equal annual installments beginning on February 11, 2026, suggesting continued long-term incentive plans for management.

Industry Context

StockSavvy.ai notes that RSU vesting and subsequent tax-related dispositions are common practices in executive compensation across various industries, particularly in healthcare and life sciences, aligning executive incentives with long-term company performance. This transaction is typical for an executive receiving equity compensation.

Comparison to Industry Standards

• This type of RSU vesting and tax-related sale is a standard practice for executive compensation across publicly traded companies.
• Peers in the diagnostics and laboratory services sector, such as Quest Diagnostics (DGX) or Eurofins Scientific (ERF.PA), commonly utilize similar equity compensation structures.
• The mechanism ensures executives gain equity while fulfilling tax obligations, aligning with common global benchmarks for executive incentive plans.

Stakeholder Impact

• Shareholders: The transactions reflect standard executive compensation practices, aligning management's interests with long-term shareholder value through equity ownership.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• Future annual installments of Restricted Stock Units will vest starting February 11, 2026, as part of the existing grant.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation (RSU vesting and tax-related sales). It does not provide new fundamental information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals rather than this specific insider transaction.

Keywords

Labcorp Holdings Inc., LH, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Stock Ownership, Executive Compensation, Peter J. Wilkinson